---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-049083"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2023-10-23T23:59:59+00:00"
generated_at: "2026-06-09T16:17:07.206274+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Catalyst announces CSRC approval for business combination with Beijing Continent

## Summary
- Beijing Continent Pharmaceuticals received CSRC approval on Oct 20, 2023 for the business combination.
- Business Combination Agreement dated Dec 26, 2022, as amended, involves Catalyst and GNI entities.
- Parties anticipate completion by the outside date as defined in the agreement.
- Closing remains subject to satisfaction of other conditions.

## SEC filing metadata
- accession: 0001140361-23-049083
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2023-10-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036123049083/0001140361-23-049083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036123049083/ef20012969_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-049083
- JSON: https://secwatch.observer/filing/0001140361-23-049083.json
- Plain text: https://secwatch.observer/filing/0001140361-23-049083.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.